MDNA Life Sciences Overview
- Year Founded
-
2014

- Status
-
IPO Registration
- Employees
-
12

- Latest Deal Type
-
IPO
- (Announced)
- Latest Deal Amount
-
$13.5M
- Investors
-
1
MDNA Life Sciences General Information
Description
Developer of mitochondrial genome-based molecular tests designed to diagnose and treat cancer. The company is focused on the development of liquid biopsy tests based on the mitochondrial genome.
Contact Information
Website
www.mdnalifesciences.comCorporate Office
- 2054 Vista Parkway
- Suite 400
- West Palm Beach, FL 33411
- United States
Corporate Office
- 2054 Vista Parkway
- Suite 400
- West Palm Beach, FL 33411
- United States
MDNA Life Sciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. IPO | 05-Aug-2022 | $13.5M | Announced | Generating Revenue | ||
4. Angel (individual) | 18-Jan-2019 | Completed | Generating Revenue | |||
3. Angel (individual) | 12-Mar-2018 | Completed | Generating Revenue | |||
2. Angel (individual) | 26-Jun-2015 | $100K | $100K | Completed | Generating Revenue | |
1. University Spin-Out | 03-Nov-2014 | Completed | Startup |
MDNA Life Sciences Comparisons
Industry
Financing
Details
MDNA Life Sciences Competitors (2)
One of MDNA Life Sciences’s 2 competitors is GRAIL, a Formerly VC-backed company based in Menlo Park, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
GRAIL | Formerly VC-backed | Menlo Park, CA | ||||
SAGA Diagnostics | Venture Capital-Backed | Lund, Sweden |
MDNA Life Sciences Patents
MDNA Life Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3899050-A2 | Mitochondrial dna deletions associated with endometriosis | Pending | 22-Dec-2018 | ||
AU-2019401465-A1 | Mitochondrial dna deletions associated with endometriosis | Pending | 22-Dec-2018 | ||
US-20220251655-A1 | Mitochondrial dna deletions associated with endometriosis | Pending | 22-Dec-2018 | ||
CA-3124497-A1 | Mitochondrial dna deletions associated with endometriosis | Pending | 22-Dec-2018 | ||
CA-2756824-A1 | Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor | Inactive | 29-Mar-2010 | C12Q1/6886 |
MDNA Life Sciences Signals
MDNA Life Sciences Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Newcastle University | University |
MDNA Life Sciences FAQs
-
When was MDNA Life Sciences founded?
MDNA Life Sciences was founded in 2014.
-
Where is MDNA Life Sciences headquartered?
MDNA Life Sciences is headquartered in West Palm Beach, FL.
-
What is the size of MDNA Life Sciences?
MDNA Life Sciences has 12 total employees.
-
What industry is MDNA Life Sciences in?
MDNA Life Sciences’s primary industry is Biotechnology.
-
Is MDNA Life Sciences a private or public company?
MDNA Life Sciences is a Private company.
-
What is the current valuation of MDNA Life Sciences?
The current valuation of MDNA Life Sciences is
. -
What is MDNA Life Sciences’s current revenue?
The current revenue for MDNA Life Sciences is
. -
How much funding has MDNA Life Sciences raised over time?
MDNA Life Sciences has raised $1.21M.
-
Who are MDNA Life Sciences’s investors?
Newcastle University has invested in MDNA Life Sciences.
-
Who are MDNA Life Sciences’s competitors?
GRAIL and SAGA Diagnostics are competitors of MDNA Life Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »